Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals Co's Other Current Payables for the quarter that ended in Jun. 2026 was NT$4,879 Mil.
Bora Pharmaceuticals Co's quarterly Other Current Payables
increased
from Dec. 2025 (NT$2,520 Mil) to Mar. 2026 (NT$3,509 Mil) and
increased
from Mar. 2026 (NT$3,509 Mil) to Jun. 2026 (NT$4,879 Mil).
Bora Pharmaceuticals Co's annual Other Current Payables
increased
from Dec. 2023 (NT$1,527 Mil) to Dec. 2024 (NT$3,277 Mil) but then
declined
from Dec. 2024 (NT$3,277 Mil) to Dec. 2025 (NT$2,520 Mil).
Bora Pharmaceuticals Co Other Current Payables Related Terms
Bora Pharmaceuticals Co Other Current Payables Historical Data
* Premium members only.
The historical data trend for Bora Pharmaceuticals Co's Other Current Payables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co Other Current Payables Chart
Bora Pharmaceuticals Co Other Current Payables Calculation
Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.
What does a Other Current Payables of NT$4,879 Mil mean?
Bora Pharmaceuticals Co (TPE:6472) has a Other Current Payables of NT$4,879 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Bora Pharmaceuticals Co and its competitors.
Is Bora Pharmaceuticals Co's Other Current Payables too high?
Bora Pharmaceuticals Co's current Other Current Payables is NT$4,879 Mil. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Other Current Payables compare to ZTS?
Bora Pharmaceuticals Co's Other Current Payables of NT$4,879 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Bora Pharmaceuticals Co and its competitors. Bora Pharmaceuticals Co's current Other Current Payables is NT$4,879 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$722.99, compared to a current price of NT$411.50 — trading 43.1% below its estimated fair value. The current Other Current Payables is NT$4,879 Mil. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Other Current Payables is NT$4,879 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$411.50 is trading 43.1% below its estimated GF Value™ of NT$722.99.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
Other Current Payables: NT$4,879 Mil
GF Value™: NT$722.99 vs. price of NT$411.50 (43.1% below fair value)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
